Copyright
©The Author(s) 2017.
World J Clin Oncol. Jun 10, 2017; 8(3): 266-272
Published online Jun 10, 2017. doi: 10.5306/wjco.v8.i3.266
Published online Jun 10, 2017. doi: 10.5306/wjco.v8.i3.266
Table 1 Quality assessment of selected randomized clinical trials evaluated by Cochrane Risk-of-Bias Tool (Risk of bias per study)
Criteria | Langer | Portier | Nordlinger | Ychou | Primrose |
Random sequence generation | Unclear | Low | Low | Low | Low |
Allocation concealments | Low | Low | Low | Low | Low |
Blinding of participants and personnel1 | Low | Low | Unclear | Low | Low |
Blinding of outcome assessment1,2 | Low | Low | Low | Low | Low |
Incomplete outcome data | Unclear | Low | Low | Unclear | Low |
Selective reporting | Low | Low | Low | Low | Low |
Other bias | Unclear | Low | Low | Low | Low |
- Citation: Araujo RLC, Herman P, Riechelmann RP. Recurrence-free survival as a putative surrogate for overall survival in phase III trials of curative-intent treatment of colorectal liver metastases: Systematic review. World J Clin Oncol 2017; 8(3): 266-272
- URL: https://www.wjgnet.com/2218-4333/full/v8/i3/266.htm
- DOI: https://dx.doi.org/10.5306/wjco.v8.i3.266